瑞德西韦在Covid-19治疗中的研究开题报告

1. 研究目的与意义（文献综述包含参考文献）

Remdesivir, developed by Gilead Sciences INC., could be a broad-spectrum antiviral treatment given by daily infusion for ten days. It's shown promise in animal models for the treatment of SARS-CoV-2 infections (the virus that causes COVID-19) and has been studied in varied clinical studies; hospital patients with advanced COVID-19 and respiratory organ involvement WHO received remdesivir , recovered quicker than similar patients WHO received placebo. This resulted during a preliminary knowledge analysis from a irregular, controlled trial with one, 063 patients that started on February twenty one. The study (known because the adaptational COVID-19 Treatment Study (ASSERTIVE COMMUNITY TREATMENT TEAM), sponsored by the National Institute of hypersensitivity reaction and Infectious Diseases (NIAID), a part of the National Institutes of Health, is that the 1st clinical study to be conducted within the u. s. was launched to guage experimental treatment for COVID -19. Associate in Nursing freelance knowledge and security observance committee (DSMB) that oversaw the study met on Apr twenty seven to review the information and share its interim analysis with the study team. supported their review of the information, they determined that remdesivir was higher than placebo, a metric usually employed in contagious disease studies, from the first termination, time to recovery, and therefore the recovery during this study was thought-about ok outlined for discharge from hospital or come back to traditional activity level. Preliminary results show that patients WHO received remdesivir did a unique job Recovered thirty first quicker than patients WHO received placebo (p

2. 研究的基本内容、问题解决措施及方案

1. Problems to be studied or solved in this topic：In this paper, the matter of subject of is Remdesivir itself. Yet the approach of study is broad and the clinical trials are ongoing. However the initial trials of the remdesivir among other medicaments are superiorly promising. Engagement of Remdesivir in treatment of coronavirus Covid-19 are monitored and reflected in beneficial results, so Remdesivir could the main candidate in the current situation, when the explicit vaccine is absent.2. Research tools to be usedEarly knowledge from a controlled trial dispensed by the U.S. National Institutes of Health, suggests that Remdesivir is effective in reducing the recovery time from fifteen to eleven days in individuals seriously sick with COVID19. On twenty nine Apr 2020, supported results of the Adaptive COVID-19 Treatment Trial (ACTT), the National Institute of allergic reaction and Infectious Diseases (NIAID) declared that Remdesivir was higher than a placebo in reducing time to recovery for individuals hospitalized with advanced COVID19 and respiratory organ involvement. Supported the results of its study, the National Institutes of Health stopped the trial and provided Remdesivir to participants allotted to received placebo. In Apr 2020, the Medicines Agency started a 'rolling review' of information on the employment of remdesivir in COVID19. So the all the information is being gathered form open source reports and clinical trial results.